{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:49:11Z","timestamp":1776854951585,"version":"3.51.2"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40258-026-01035-5","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:51:20Z","timestamp":1773215480000},"page":"597-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness and Public Health Impact of Newborn Screening for Spinal Muscular Atrophy in France"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8074-5480","authenticated-orcid":false,"given":"Sebastien","family":"Eymere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oyin","family":"Opeifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Sivignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Cayre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymeric","family":"de Chasteigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Leiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Laugel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"1035_CR1","unstructured":"Prior TW, Leach ME, Finanger E. Spinal muscular atrophy. GeneReviews\u00ae; 2000. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1352\/."},{"key":"1035_CR2","unstructured":"HAS. Newborn screening for spinal muscular atrophy\u2014advance assessment of extension of screening to the general population in France. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-09\/newborn_screening_for_spinal_muscular_atrophy_advance_assessment_of_extension_of_screening_to_the_general_population_in_fran.pdf. Accessed 27 Sept 2024."},{"key":"1035_CR3","unstructured":"HAS. Avis sur les m\u00e9dicaments: Zolgensma 2x10^3 g\u00e9nomes du vecteur\/mL solution pour perfusion Saint-Denis: Haute Autorit\u00e9 de Sant\u00e9; 2023."},{"key":"1035_CR4","doi-asserted-by":"publisher","unstructured":"Grimaldi L, Garcia-Uzquiano R, de la Banda MG-G, et al. REGISTRE SMA FRANCE: a nationwide observational registry of patients with spinal muscular atrophy in France. J Neuromuscul Dis. 2025;12(6):793\u2013803. https:\/\/doi.org\/10.1177\/22143602251353446.","DOI":"10.1177\/22143602251353446"},{"issue":"3","key":"1035_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, et al. Muscle strength and motor function throughout life in a cross\u2010sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol. 2018;25(3):512\u20138. https:\/\/doi.org\/10.1111\/ene.13534.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1035_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3233\/jnd-200610","volume":"8","author":"HJ McMillan","year":"2021","unstructured":"McMillan HJ, Gerber B, Cowling T, et al. Burden of spinal muscular atrophy (SMA) on patients and caregivers in Canada. J Neuromuscul Dis. 2021;8(4):553\u201368. https:\/\/doi.org\/10.3233\/jnd-200610.","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"1035_CR7","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Leary R, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264(7):1465\u201373. https:\/\/doi.org\/10.1007\/s00415-017-8549-1.","journal-title":"J Neurol"},{"key":"1035_CR8","unstructured":"Vidal. How is proximal spinal muscular atrophy treated? https:\/\/www.vidal.fr\/maladies\/systeme-nerveux\/amyotrophies-spinales-proximales\/traitements.html. Accessed 3 June 2024."},{"key":"1035_CR9","unstructured":"EMA. Evrysdi. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi#authorisation-details. Accessed 3 June 2024."},{"key":"1035_CR10","unstructured":"EMA. Spinraza. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza. Accessed 3 June 2024."},{"key":"1035_CR11","unstructured":"EMA. Zolgensma. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma. Accessed 3 June 2024."},{"key":"1035_CR12","unstructured":"Filnemus. Protocole National de Diagnostic et de Soins (PNDS): amyotrophie spinale infantile. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-03\/amyotrophie_spinale_infantile_-_pnds.pdf. Accessed 6 June 2024."},{"key":"1035_CR13","unstructured":"Waldrop MA, Escudero RB, Camarata RA et al. Long-term follow-up of onasemnogene abeparvovec gene therapy for patients with spinal muscular atrophy type 1 from the START trial. In: Muscular dystrophy association clinical & scientific conference. Dallas Tx. p. 2025."},{"key":"1035_CR14","unstructured":"Quijano-Roy. French SMA Registry\u2014standard annual statistical report. In: AP-HP, ed. Paris: AP-HP; 2024."},{"issue":"1","key":"1035_CR15","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.jval.2021.11.205","volume":"25","author":"D Beziz","year":"2022","unstructured":"Beziz D, Guye S, Marchal C, et al. POSA60 clinical and economic burden of spinal muscular atrophy in France. Value Health. 2022;25(1):S44\u20135. https:\/\/doi.org\/10.1016\/j.jval.2021.11.205.","journal-title":"Value Health"},{"key":"1035_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1062390","author":"S Boursange","year":"2022","unstructured":"Boursange S, Araneda M, Stalens C, et al. Parents\u2019 dilemma: a therapeutic decision for children with spinal muscular atrophy (SMA) type 1. Front Pediatr. 2022. https:\/\/doi.org\/10.3389\/fped.2022.1062390.","journal-title":"Front Pediatr"},{"issue":"5","key":"1035_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1051\/medsci\/2021052","volume":"37","author":"J-P Farriaux","year":"2021","unstructured":"Farriaux J-P. Histoire et organisation du programme Fran\u00e7ais de d\u00e9pistage n\u00e9onatal syst\u00e9matique (1967\u20132020). Med Sci (Paris). 2021;37(5):433\u201340. https:\/\/doi.org\/10.1051\/medsci\/2021052.","journal-title":"Med Sci (Paris)"},{"key":"1035_CR18","unstructured":"HAS. Note de Cadrage : d\u00e9pistage n\u00e9onatal de l'amyotrophie spinale. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2023-07\/note_de_cadrage_depistage_neonatal_amyotrophie_spinale_vf.pdf. Accessed 3 June 2024."},{"key":"1035_CR19","unstructured":"Loi n\u00b0 2021-1017 du 2 ao\u00fbt 2021 relative \u00e0 la bio\u00e9thique. Code de la Sant\u00e9 publique. 2021. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000043884384."},{"key":"1035_CR20","unstructured":"HAS. La HAS propose l\u2019extension du d\u00e9pistage n\u00e9onatal \u00e0 l\u2019amyotrophie spinale. https:\/\/www.has-sante.fr\/jcms\/p_3529765\/fr\/la-has-propose-l-extension-du-depistage-neonatal-a-l-amyotrophie-spinale. Accessed 21 July 2025."},{"issue":"9","key":"1035_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40261-024-01386-8","volume":"44","author":"G Ghetti","year":"2024","unstructured":"Ghetti G, Mennini FS, Marcellusi A, Bischof M, Pistillo GM, Pane M. Cost-effectiveness analysis of newborn screening for spinal muscular atrophy in Italy. Clin Drug Investig. 2024;44(9):687\u2013701. https:\/\/doi.org\/10.1007\/s40261-024-01386-8.","journal-title":"Clin Drug Investig"},{"key":"1035_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2439734","author":"AA-O Hata","year":"2025","unstructured":"Hata AA-O, Uda AA-O, Tanaka SA-O, et al. Cost-utility analysis of newborn screening for spinal muscular atrophy in Japan. J Med Econ. 2025. https:\/\/doi.org\/10.1080\/13696998.2024.2439734.","journal-title":"J Med Econ"},{"issue":"10","key":"1035_CR23","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","volume":"25","author":"R Velikanova","year":"2022","unstructured":"Velikanova R, van der Schans S, Bischof M, van Olden RW, Postma M, Boersma C. Cost-effectiveness of newborn screening for spinal muscular atrophy in the Netherlands. Value Health. 2022;25(10):1696\u2013704. https:\/\/doi.org\/10.1016\/j.jval.2022.06.010.","journal-title":"Value Health"},{"issue":"4","key":"1035_CR24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","volume":"12","author":"D Weidlich","year":"2023","unstructured":"Weidlich D, Servais L, Kausar I, Howells R, Bischof M. Cost-effectiveness of newborn screening for spinal muscular atrophy in England. Neurol Ther. 2023;12(4):1205\u201320. https:\/\/doi.org\/10.1007\/s40120-023-00489-2.","journal-title":"Neurol Ther"},{"key":"1035_CR25","unstructured":"HAS. Choices in methods for economic evaluation. https:\/\/www.has-sante.fr\/jcms\/r_1499251\/en\/choices-in-methods-for-economic-evaluation. Accessed 21 July 2025."},{"key":"1035_CR26","unstructured":"INSEE. Naissances et taux de natalit\u00e9: donn\u00e9es annuelles de 1982 \u00e0 2023. https:\/\/www.insee.fr\/fr\/statistiques\/2381380#tableau-figure1. Accessed 6 June 2024."},{"issue":"11","key":"1035_CR27","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007.","journal-title":"Neuromuscul Disord"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1212\/WNL.0000000000202549","volume":"100","author":"J Mendell","year":"2023","unstructured":"Mendell J, Wigderson M, Aleca I, Yang L, Mehl L, Conolly A. Long-term follow-up of onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1. Neurology (P7-9006). 2023;100:2432. https:\/\/doi.org\/10.1212\/WNL.0000000000202549.","journal-title":"Neurology (P7-9.006)"},{"key":"1035_CR29","doi-asserted-by":"publisher","unstructured":"Finkel R, Al-Muhaizea M, Farrar MA, Nelson L, Prufer A, Servais L, Wang Y, Zanoteli E, Palfreeman L, El-Khairi M, Gorni K, Kletzl H, Gerber M, Scalco RS, Bertini E. RAINBOWFISH: a study of risdiplam in newborns with presymptomatic spinal muscular atrophy. Muscular Dystrophy Assoc. 2021. https:\/\/doi.org\/10.1212\/WNL.96.15_supplement.4281","DOI":"10.1212\/WNL.96.15_supplement.4281"},{"issue":"7","key":"1035_CR30","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med. 2022;28(7):1381\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01866-4.","journal-title":"Nat Med"},{"issue":"5","key":"1035_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00700.x.","journal-title":"Value Health"},{"issue":"1","key":"1035_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146(1):67\u201372. https:\/\/doi.org\/10.1016\/S0022-510X(96)00284-5.","journal-title":"J Neurol Sci"},{"issue":"6","key":"1035_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391. https:\/\/doi.org\/10.1002\/ana.25101.","journal-title":"Ann Neurol"},{"issue":"5","key":"1035_CR34","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131(5):e1509\u201314. https:\/\/doi.org\/10.1542\/peds.2012-2278.","journal-title":"Pediatrics"},{"key":"1035_CR35","unstructured":"HAS. Avis Economique: ZOLGENSMA (onasemnogene abeparvovec) Traitement de l\u2019amyotrophie spinale chez des patients pr\u00e9symptomatiques avec une d\u00e9l\u00e9tion biall\u00e9lique du g\u00e8ne SMN1 et jusqu\u2019\u00e0 3 copies du g\u00e8ne SMN2. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-01\/zolgensma_21112023_avis_economique_pret_a_publier.pdf. Accessed 3 June 2024."},{"key":"1035_CR36","unstructured":"l'Assurance Maladie. Base des m\u00e9dicaments et informations tarifaires. http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/index_presentation.php?p_site=AMELI."},{"key":"1035_CR37","unstructured":"AFPA. AFPA-CRESS\/Inserm-CompuGroup Medical 2018 curves for boys. https:\/\/afpa.org\/outil\/courbes-de-croissance-garcons-francais\/. Accessed 21 July 2025."},{"key":"1035_CR38","unstructured":"AFPA. AFPA-CRESS\/Inserm-CompuGroup Medical 2018 curves for girls. https:\/\/afpa.org\/outil\/courbes-de-croissance-filles-francaises\/. Accessed 21 July 2025."},{"key":"1035_CR39","unstructured":"InnovAction. D\u00e9cisions th\u00e9rapeutiques RCP p\u00e9diatrique\u2014Septembre 2022\u2014Septembre 2023. 2023. Accessed 21 July 2025."},{"key":"1035_CR40","unstructured":"INSEE. Indice des prix \u00e0 la consummation\u2014Base 2015\u2014Ensemble des m\u00e9nages\u2014France\u2014Services de sant\u00e9. https:\/\/www.insee.fr\/fr\/statistiques\/serie\/001763845. Accessed 3 June 2024."},{"key":"1035_CR41","unstructured":"Finances Igd. Revue de d\u00e9penses 2016\u2014Les transports sanitaires. https:\/\/www.igf.finances.gouv.fr\/igf\/accueil\/nos-activites\/rapports-de-missions\/liste-de-tous-les-rapports-de-mi\/revue-de-depenses-2016---les-tra.html. Accessed 7 June 2024."},{"key":"1035_CR42","unstructured":"HAS. Zolgensma (onasemnogene abeparvovec). HAS; 2020."},{"key":"1035_CR43","unstructured":"HAS. Avis sur les m\u00e9dicaments: Zolgensma 2x10^3 vector genomes\/mL solution for infusion. https:\/\/www.has-sante.fr\/jcms\/p_3473774\/fr\/zolgensma-10052023-summary-ct20080. Accessed 3 June 2024."},{"issue":"1","key":"1035_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/dmcn.15286","volume":"65","author":"T Dangouloff","year":"2023","unstructured":"Dangouloff T, Hiligsmann M, Deconinck N, et al. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Dev Med Child Neurol. 2023;65(1):67\u201377. https:\/\/doi.org\/10.1111\/dmcn.15286.","journal-title":"Dev Med Child Neurol"},{"key":"1035_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0695-0","author":"J L\u00f3pez-Bastida","year":"2017","unstructured":"L\u00f3pez-Bastida J, Pe\u00f1a-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017. https:\/\/doi.org\/10.1186\/s13023-017-0695-0.","journal-title":"Orphanet J Rare Dis"},{"key":"1035_CR46","unstructured":"NICE. Risdiplam for treating spinal muscular atrophy TA755. 2021. https:\/\/www.nice.org.uk\/guidance\/ta755. Accessed 30 Jan 2026."},{"issue":"3","key":"1035_CR47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1741-3729.2010.00601.x","volume":"59","author":"J Song","year":"2010","unstructured":"Song J, Floyd FJ, Seltzer MM, Greenberg JS, Hong J. Long\u2010term effects of child death on parents\u2019 health\u2010related quality of life: a dyadic analysis. Fam Relat. 2010;59(3):269\u201382. https:\/\/doi.org\/10.1111\/j.1741-3729.2010.00601.x.","journal-title":"Fam Relat"},{"key":"1035_CR48","unstructured":"Novartis. Epid\u00e9miologie et prise en charge th\u00e9rapeutique des patients atteints d\u2019amyotrophie spinale en France de 2011 \u00e0 2022. 2024."},{"issue":"1","key":"1035_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1001\/jamapediatrics.2014.2465","volume":"169","author":"JP Brosco","year":"2015","unstructured":"Brosco JP, Grosse SD, Ross LF. Universal state newborn screening programs can reduce health disparities. JAMA Pediatr. 2015;169(1):7\u20138. https:\/\/doi.org\/10.1001\/jamapediatrics.2014.2465.","journal-title":"JAMA Pediatr"},{"issue":"2","key":"1035_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1503\/cmaj.050584","volume":"174","author":"E van Doorslaer","year":"2006","unstructured":"van Doorslaer E, Masseria C, Koolman X, Group OHER. Inequalities in access to medical care by income in developed countries. CMAJ. 2006;174(2):177\u201383. https:\/\/doi.org\/10.1503\/cmaj.050584.","journal-title":"CMAJ"},{"issue":"3-4","key":"1035_CR51","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1475-5890.2016.12109","volume":"37","author":"R Cookson","year":"2016","unstructured":"Cookson R, Propper C, Asaria M, Raine R. Socio\u2010economic inequalities in health care in England. Fisc Stud. 2016;37(3\u20134):371\u2013403. https:\/\/doi.org\/10.1111\/j.1475-5890.2016.12109.","journal-title":"Fisc Stud"},{"issue":"7","key":"1035_CR52","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/01.gim.0000227935.26763.c6","volume":"8","author":"SD Grosse","year":"2006","unstructured":"Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? Genet Med. 2006;8(7):448\u201350. https:\/\/doi.org\/10.1097\/01.gim.0000227935.26763.c6.","journal-title":"Genet Med"},{"key":"1035_CR53","unstructured":"Officiel J. Arr\u00eat\u00e9 du 16 avril 2025 modifiant l'arr\u00eat\u00e9 du 22 f\u00e9vrier 2018 relatif \u00e0 l'organisation du programme national de d\u00e9pistage n\u00e9onatal recourant \u00e0 des examens de biologie m\u00e9dicale. JORF no. 0102 30 April 2025 Paris."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01035-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01035-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01035-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:03:01Z","timestamp":1776852181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-026-01035-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1007\/s40258-026-01035-5","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marine Sivignon, Aur\u00e9lie Meunier, Oyin Opeifa, and S\u00e9bastien Eymere are employees of Putnam. Putnam received fees from Novartis to conduct the study. Pr. Laugel reports fees for consultancies, outside the present work, from Roche, Biogen, Novartis, Santhera, Pfizer, Sarepta, PTC Therapeuticsm and Italfarmaco. Pr. Isabelle Borget received fees from Novartis to be part of the scientific committee of this economic evaluation. Fanny Cayre, Aymeric de Chasteigner, and Guillaume Leiba are employed by Novartis AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}},{"value":"All authors contributed to the study conception and design. Model adaptation and data analysis were performed by the health economics research team: Sebastien Eymere, Oyin Opeifa, Aur\u00e9lie Meunier, and Marine Sivignon. Clinical and health policy input was provided by experts involved in newborn screening, SMA management, and health economics in France. All authors contributed to the interpretation of results. Sebastien Eymere, Oyin Opeifa, Aur\u00e9lie Meunier, and Marine Sivignon drafted the manuscript. All authors critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Individual Contributions"}},{"value":"This study did not involve human participants or animals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication (from Patients\/Participants)"}},{"value":"The data and materials supporting the findings of this study are not publicly available owing to commercial confidentiality restrictions but may be available from the corresponding author upon reasonable request and subject to appropriate agreements.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The economic model code is not publicly available owing to commercial confidentiality.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}